Sign in or create an account to add this stock to your watchlist.
About Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-9.28
Forward P/E Ratio-6.32
Sales & Book Value
Annual Sales$2.46 million
Price / Sales43.03
Price / CashN/A
Book Value$1.44 per share
Price / Book5.09
EPS (Most Recent Fiscal Year)($0.79)
Return on Equity-49.15%
Return on Assets-25.54%
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
2 Wall Street analysts have issued 12 month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $22.50 in the next twelve months. View Analyst Ratings for Oramed Pharmaceuticals.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Depomed (DEPO), Clearside Biomedical (CLSD), Merus (MRUS), American Brivision (Holding) (ABVC), MediciNova (MNOV), Evolus (EOLS), Synergy Pharmaceuticals (SGYP), Albireo (ALBO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), ArQule (ARQL), Innovate (INNT), Kala Pharmaceuticals (KALA), Unum Therapeutics (UMRX) and Paratek Pharmaceuticals (PRTK).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Mr. Nadav Kidron Esq., Pres, CEO & Exec. Director (Age 44)
- Mr. Joshua Hexter, COO & VP of Bus. Devel. (Age 48)
- Dr. Miriam Kidron Ph.D., Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 78)
- Ms. Hilla Eisenberg CPA, CFO, Treasurer, Sec. and Principal Financial & Accounting Officer (Age 34)
- Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
Has Oramed Pharmaceuticals been receiving favorable news coverage?
Press coverage about ORMP stock has been trending positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 0.29 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $7.33.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $108.03 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oramed Pharmaceuticals (NASDAQ:ORMP) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 1.91%
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/2/2017||Xiaopeng Li||Director||Buy||89,636||$8.50||$761,906.00||206,350|| |
|4/19/2017||Miriam Kidron||Insider||Sell||52,814||$6.33||$334,312.62|| |
|5/12/2016||Nadav Kidron||CEO||Buy||1,000||$6.95||$6,950.00||957,448|| |
|12/30/2015||Miriam Kidron||CTO||Sell||50,000||$8.90||$445,000.00||142,450|| |
|12/9/2015||Michael Berelowitz||Director||Sell||700||$9.44||$6,608.00||22,896|| |
|12/8/2015||Michael Berelowitz||Director||Sell||1,300||$8.70||$11,310.00||23,596|| |
|3/19/2015||Nadav Kidron||CEO||Buy||2,600||$3.88||$10,088.00|| |
|9/11/2014||Miriam Kidron||CTO||Sell||31,699||$8.41||$266,588.59|| |
|9/10/2014||Miriam Kidron||CTO||Sell||23,000||$8.40||$193,200.00|| |
|9/4/2014||Miriam Kidron||CTO||Sell||8,301||$9.41||$78,112.41|| |
|6/6/2014||Regals Capital Management Lp||Major Shareholder||Buy||2,252||$4.44||$9,998.88|| |
|3/31/2014||Michael Berelowitz||Director||Sell||9,434||$10.50||$99,057.00|| |
|3/25/2014||Regals Capital Management Lp||major shareholder||Buy||75,000||$10.62||$796,500.00|| |
|2/6/2014||Regals Capital Management Lp||major shareholder||Buy||51,292||$15.61||$800,668.12|| |
|7/10/2013||Regals Capital Management Lp||Major Shareholder||Buy||6,630||$7.40||$49,062.00|| |
Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines
|Oramed Pharmaceuticals (ORMP) Lifted to Sell at ValuEngine|
www.americanbankingnews.com - May 14 at 6:57 AM
|Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a ...|
www.prnewswire.com - May 10 at 5:56 PM
|ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Strong Sell|
www.americanbankingnews.com - May 8 at 11:26 PM
|Oramed to Present at Conferences in May|
finance.yahoo.com - May 7 at 5:37 PM
|Oramed Pharmaceuticals (ORMP) Upgraded to Hold by ValuEngine|
www.americanbankingnews.com - April 25 at 8:24 AM
|Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin|
finance.yahoo.com - April 23 at 5:13 PM
|Oramed Pharmaceuticals (ORMP) Cut to Sell at ValuEngine|
www.americanbankingnews.com - April 20 at 12:24 AM
|FY2018 Earnings Estimate for Oramed Pharmaceuticals Inc. Issued By B. Riley (ORMP)|
www.americanbankingnews.com - April 19 at 7:18 AM
|Form 4 ORAMED PHARMACEUTICALS For: Apr 08 Filed by: Hexter Joshua|
www.streetinsider.com - April 11 at 8:31 AM
|Oramed Pharmaceuticals (ORMP) Raised to Hold at ValuEngine|
www.americanbankingnews.com - April 10 at 12:32 AM
|Oramed Pharmaceuticals (ORMP) Given "Buy" Rating at B. Riley|
www.americanbankingnews.com - March 28 at 12:58 PM
|Oramed to Present at HC Wainwright Annual Global Life Sciences Conference|
www.prnewswire.com - March 27 at 5:13 PM
|Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference|
finance.yahoo.com - March 27 at 8:28 AM
|Oramed to Present at Oppenheimer's Annual Healthcare Conference - PR Newswire (press release)|
www.prnewswire.com - March 16 at 8:21 AM
|Oramed to Present at Oppenheimer's Annual Healthcare Conference|
finance.yahoo.com - March 15 at 6:11 PM
|Oramed Adds Two New Members to its Scientific Advisory Board - PR Newswire (press release)|
www.prnewswire.com - March 1 at 8:15 AM
|Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension - PR Newswire (press release)|
www.prnewswire.com - February 22 at 8:22 AM
|Oramed Pharmaceuticals (ORMP) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - February 21 at 12:56 AM
|Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension|
finance.yahoo.com - February 20 at 5:46 PM
|Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)|
www.americanbankingnews.com - February 10 at 12:44 PM
|Oramed to Present at BIO CEO Investor Conference - PR Newswire (press release)|
www.prnewswire.com - February 8 at 8:11 AM
|Oramed to Present at BIO CEO Investor Conference|
finance.yahoo.com - February 6 at 9:33 AM
|FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research|
www.americanbankingnews.com - February 1 at 12:32 PM
|Oramed Pharmaceuticals' CEO Issues Letter to Shareholders|
www.bizjournals.com - January 19 at 11:48 AM
|Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018|
finance.yahoo.com - January 19 at 11:48 AM
|Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.'s FY2018 Earnings (ORMP)|
www.americanbankingnews.com - January 18 at 2:58 PM
|Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy|
finance.yahoo.com - January 18 at 11:16 AM
|Oramed Pharmaceuticals (ORMP) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - January 1 at 2:20 PM
|Oramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to Hold|
www.americanbankingnews.com - December 23 at 4:14 PM
|Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share|
www.americanbankingnews.com - December 13 at 10:26 AM
|Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reaffirmed at B. Riley|
www.americanbankingnews.com - December 11 at 10:10 PM
|B.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.com|
www.streetinsider.com - December 11 at 4:44 PM
|ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell|
www.americanbankingnews.com - December 5 at 10:12 PM
|Here's Why And How Oramed Pharmaceuticals Is Going After NASH|
www.benzinga.com - November 28 at 4:31 PM
|Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reiterated at HC Wainwright|
www.americanbankingnews.com - November 22 at 8:40 AM
| Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00|
www.americanbankingnews.com - November 20 at 10:32 AM
|Reviewing Oramed Pharmaceuticals (ORMP) and Its Peers|
www.americanbankingnews.com - November 19 at 9:26 PM
|Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals|
www.americanbankingnews.com - November 19 at 3:30 PM
|FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints - Nasdaq|
www.nasdaq.com - November 15 at 7:10 AM
|Oramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.com|
www.streetinsider.com - November 15 at 7:10 AM
|Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule|
finance.yahoo.com - November 15 at 7:10 AM
|Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins|
www.streetinsider.com - November 2 at 7:22 AM
|Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.com|
www.streetinsider.com - November 1 at 7:18 AM
|Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins|
finance.yahoo.com - November 1 at 7:18 AM
|Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00|
www.americanbankingnews.com - October 30 at 4:02 AM
|Oramed to Present at the Diabetes Technology Meeting|
finance.yahoo.com - October 25 at 8:42 AM
|Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its Scientists|
www.streetinsider.com - October 18 at 1:50 AM
|Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.com|
www.streetinsider.com - October 17 at 3:45 PM
|Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists|
finance.yahoo.com - October 17 at 3:45 PM
|Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)|
www.americanbankingnews.com - October 7 at 6:28 PM
Oramed Pharmaceuticals (NASDAQ:ORMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oramed Pharmaceuticals (NASDAQ:ORMP) Income Statement, Balance Sheet and Cash Flow Statement
Oramed Pharmaceuticals (NASDAQ ORMP) Stock Chart for Thursday, May, 24, 2018